Seeks to further amend notification No. 16/2017-Customs, dated the 20th April, 2017 so to exempt certain drugs for supply under Patient Assistance Programme run by specified pharmaceutical companies.

X X   X X   Extracts   X X   X X

Full Text of the Document

X X   X X   Extracts   X X   X X

....toms New Delhi, the 1st February, 2025 G.S.R. 102 (E).- In exercise of the powers conferred by sub-section (1) of section 25 of the Customs Act, 1962 (52 of 1962), the Central Government, on being satisfied that it is necessary in the public interest so to do, hereby makes the following further amendments in the notification of the Government of India in the Ministry of Finance (Department of Re....

X X   X X   Extracts   X X   X X

Full Text of the Document

X X   X X   Extracts   X X   X X

.... Dabrafenib UMAANG Novartis Healthcare Pvt. Ltd. 60. Selumetinib AstraZeneca Pharma PAP AstraZeneca Pharma India Limited 61. Benralizumab AstraZeneca Pharma PAP AstraZeneca Pharma India Limited 62. Fulvestrant AstraZeneca Pharma PAP AstraZeneca Pharma India Limited 63. Acalabrutinib AstraZeneca Pharma PAP AstraZeneca Pharma India Limited 64. Olaparib Astr....

X X   X X   Extracts   X X   X X

Full Text of the Document

X X   X X   Extracts   X X   X X

.... Merck Specialties Pvt. Ltd. 75. Brentuximab Vedotin Takeda PAP Takeda Biopharmaceuticals India Pvt. Limited 76. Vedolizumab Takeda PAP Takeda Biopharmaceuticals India Pvt. Limited 77. Velaglucerase Alpha Takeda PAP Takeda Biopharmaceuticals India Pvt. Limited 78. Agalsidase Alpha Takeda PAP Takeda Biopharmaceuticals India Pvt. Limited 79. Idursulphase Takeda ....